| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Rp-cAMPS triethylammonium salt targets cAMP-dependent protein kinase A (PKA), a key enzyme in the cAMP signaling pathway. It acts as a competitive antagonist by interacting with cAMP binding sites on the regulatory subunits of PKA I and II, preventing cAMP-induced activation. It has Ki values of 12.5 µM and 4.5 µM for PKA I and II, respectively. The compound is resistant to hydrolysis by phosphodiesterases, making it a stable cAMP analog for research applications.
|
|---|---|
| ln Vitro |
In order to prevent PKA activation, a membrane-permeable competitive cAMP antagonist (Rp-cAMPS) binds to the regulatory subunit without causing the kinase holoenzyme to dissociate. It has little effect on regular synaptic transmission, but it also suppresses synaptic plasticity [2].
In vitro studies have demonstrated that Rp-cAMPS triethylammonium salt is a potent, competitive antagonist of cAMP-induced activation of PKA I and II. It has IC50 values of 12.5 µM and 4.5 µM for PKA I and II, respectively, and Ki values of 6.05 µM and 9.75 µM. The compound is cell-permeable and resistant to hydrolysis by phosphodiesterases. It is widely used in scientific research to study cAMP signaling and PKA-mediated cellular processes. |
| ln Vivo |
In slices from arthritic rats, Rp-cAMPS (10 μM, 15 min) decreases monosynaptic EPSCs evoked by PB-CeLC and BLA-CeLC synapses, but not in control neurons from normal animals. When compared to pre-drug (ACSF) control values obtained in the same neurons, the inhibitory effect of Rp-cAMPS was significant [2].
In vivo studies with Rp-cAMPS triethylammonium salt are limited, as the compound is primarily used as a research tool in vitro. However, as a cell-permeable cAMP analog, it can be administered to animal models to study the role of cAMP-PKA signaling in various physiological and pathological processes. The compound's ability to antagonize PKA activation makes it useful for studying PKA-mediated signaling in vivo. Detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound is intended for research purposes only. |
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Rp-cAMPS triethylammonium salt typically involve PKA inhibition studies using purified PKA holoenzyme. The enzyme is incubated with increasing concentrations of Rp-cAMPS (0.1 µM - 1 mM) and a fixed concentration of cAMP (the activator) and a peptide substrate (e.g., Kemptide or other PKA substrate) in the presence of ³³P-ATP in assay buffer at 30°C for 10-30 minutes. Phosphorylation of the substrate is measured by filter binding or by scintillation counting. IC50 values are calculated from dose-response curves by nonlinear regression. The compound's resistance to phosphodiesterases can be confirmed by incubation with phosphodiesterase and measuring cAMP degradation.
|
| Cell Assay |
For in vitro cell-based assays, various cell lines are cultured in appropriate media. Cells are treated with Rp-cAMPS triethylammonium salt at concentrations ranging from 1-100 µM for 1-24 hours. PKA inhibition is confirmed by measuring the phosphorylation of PKA substrates (e.g., CREB, VASP) via Western blot. cAMP signaling can be modulated by treating cells with forskolin (to stimulate adenylyl cyclase) or other cAMP-elevating agents with or without Rp-cAMPS pretreatment. Cellular responses such as gene expression (e.g., CREB-dependent transcription), cell morphology, or proliferation are assessed. Cell viability is assessed by MTT or CCK-8 assays. The compound's cell permeability allows direct application to cultured cells.
|
| Animal Protocol |
In vivo animal studies with Rp-cAMPS triethylammonium salt are limited. The compound could be administered intraperitoneally or intravenously to rodents to study the role of PKA in various physiological processes. However, specific published protocols are limited. The compound's cell-permeable nature suggests it could be used in vivo, but pharmacokinetic data are not widely available. The compound is primarily used as a research reagent for in vitro studies of cAMP-PKA signaling.
|
| ADME/Pharmacokinetics |
Rp-cAMPS triethylammonium salt has a molecular weight of 446.46 g/mol and molecular formula C16H27N6O5PS. The compound is soluble in water and DMSO. It is resistant to hydrolysis by phosphodiesterases, making it a stable cAMP analog. Storage recommendations: -20°C. The compound is cell-permeable. Pharmacokinetic properties including half-life, clearance, and distribution are not well characterized. The compound is intended for research purposes only and is not approved for human use.
|
| Toxicity/Toxicokinetics |
In preclinical studies, Rp-cAMPS triethylammonium salt has shown a manageable safety profile at research concentrations. As a cAMP analog, it is not expected to have significant toxicity at the concentrations used in cell-based assays (typically 1-100 µM). However, comprehensive toxicology studies have not been published. The compound is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Rp-cAMPS triethylammonium salt is a cell-permeable, non-hydrolyzable phosphorothioate analog of cAMP that acts as a competitive antagonist of cAMP-induced activation of PKA I and II. It has IC50 values of 12.5 µM and 4.5 µM for PKA I and II, respectively. The compound is resistant to hydrolysis by phosphodiesterases. It is widely used in scientific research to study cAMP signaling and PKA-mediated cellular processes. Rp-cAMPS triethylammonium salt is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C₁₆H₂₇N₆O₅PS
|
|---|---|
| Molecular Weight |
446.46
|
| Exact Mass |
446.15
|
| CAS # |
151837-09-1
|
| Related CAS # |
Sp-cAMPS sodium salt;142439-95-0;Rp-cAMPS sodium salt;142439-94-9;Rp-cAMPS;73208-40-9;Sp-cAMPS;71774-13-5
|
| PubChem CID |
16218857
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
212 - 213 ℃
|
| LogP |
2.049
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
528
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCN(CC)CC.C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=S)(O1)O
|
| InChi Key |
OXIPZMKSNMRTIV-NVGWRVNNSA-N
|
| InChi Code |
InChI=1S/C10H12N5O5PS.C6H15N/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(19-10)1-18-21(17,22)20-7;1-4-7(5-2)6-3/h2-4,6-7,10,16H,1H2,(H,17,22)(H2,11,12,13);4-6H2,1-3H3/t4-,6-,7-,10-,21?;/m1./s1
|
| Chemical Name |
(4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;N,N-diethylethanamine
|
| Synonyms |
RpcAMPS triethylammonium salt; Rp cAMPS triethylammonium salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2398 mL | 11.1992 mL | 22.3984 mL | |
| 5 mM | 0.4480 mL | 2.2398 mL | 4.4797 mL | |
| 10 mM | 0.2240 mL | 1.1199 mL | 2.2398 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
